JAZZ News and Press, Jazz Pharmaceuticals plc From 02/24/23

Summary Jazz Pharmaceuticals, which is known for its Oxybate drug line used to treat narcolepsy, is seeking to diversify its product portfolio beyond Oxybate in anticipation of a revenue decline. After encouraging preliminary data for the treatment of first-line metastatic, HER2+ gastro...

Summary Jazz Pharma has been unable to catch a bid into the new-year rally. Despite recent advancements, it faces additional patent challenges to its core cash producing assets. Valuations are compressed, but we've seen no valuation upside over 5-year averages. Net-net, rate hol...

Summary Zanidatamab passed the key test in December that led to partner Jazz's opt-in. HERIZON-BTC-01 results exceeded expectations with a much longer duration of response. Zanidatamab is now Jazz's responsibility and Zymeworks stands to benefit as the program moves forward. Wit...

Summary Shares of immuno-oncology concern Werewolf Therapeutics are down 80% from their April 2021 IPO pricing as a lack of clinical data has negatively impacted results. That dynamic will start to change as two of its assets enter the clinic, with a readout expected for Interleukin-2 c...

Summary Today, we take a look at a small biopharma concern called GlycoMimetics that is focused on developing treatments for disease through the inhibition of a subset of proteins known as selectins. The stock plunged more than 50% earlier this week on news of a capital raise and key tr...

Jazz Pharmaceuticals to Report 2022 Fourth Quarter and Full Year Financial Results on March 1, 2023 PR Newswire DUBLIN , Feb. 15, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2022 fourth quarter and full yea...

Cannabis stocks rose to prominence a few years ago when Canada famously legalized the recreational use of pot. And although some of that initial excitement has died down, there is no question that the industry still presents a lucrative opportunity for long-term investors. According to some estim...

Cannabis stocks had a rough time over the past year, with the EFT Alternative Harvest ETF (NYSEMKT: MJ) and the AdvisorShares Pure Cannabis ETF (NYSEMKT: YOLO) down by more than 53% and 64%, respectively. A glut of cannabis and falling revenues were the most obvious reasons fo...

The following slide deck was published by Jazz Pharmaceuticals plc in conjunction with this event. For further details see: Jazz Pharmaceuticals (JAZZ) Presents At 41st Annual Healthcare Conference - Slideshow

Jazz Pharma ( NASDAQ: JAZZ ) and Zymeworks ( NASDAQ: ZYME ) announced tolerability and efficacy results, including the first overall survival data, from a Phase 2 trial testing zanidatamab in combination with chemotherapy, in first-line patients with HER2-expressing metastatic...